

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/334712337>

Platelet disturbances correlate with endothelial cell activation in uncomplicated Plasmodium vivax malaria

Preprint · July 2019

DOI: 10.1101/715003

CITATIONS

0

READS

39

12 authors, including:



Julio Aliberti

National Institutes of Health

97 PUBLICATIONS 9,055 CITATIONS

[SEE PROFILE](#)



Diógenes Lima

University of São Paulo

7 PUBLICATIONS 80 CITATIONS

[SEE PROFILE](#)



Helder I Nakaya

University of São Paulo

184 PUBLICATIONS 6,994 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



P. vivax malaria [View project](#)



B cell signalling and metabolism on antibody-secreting cell differentiation in vitro and in Dengue patients [View project](#)

1 **TITLE: Platelet disturbances correlate with endothelial cell activation in**
2 **uncomplicated *Plasmodium vivax* malaria**

3 João Conrado Khouri Dos-Santos^{1,2}, João Luiz Silva-Filho¹, Carla C Judice¹, Ana
4 Carolina Andrade Vitor Kayano¹, Júlio Aliberti³, Ricardo Khouri⁴, Diógenes S. de
5 Lima⁵, Helder Nakaya⁵, Marcus Vinicius Guimarães Lacerda^{6,7}, Erich Vinicius De
6 Paula⁸, Stefanie Costa Pinto Lopes⁷, Fabio Trindade Maranhão Costa^{1*}

7 1. Laboratório de Doenças Tropicais – Prof. Luiz Jacintho da Silva. Instituto
8 de Biologia, Universidade Estadual de Campinas, Brazil.

9 2. Faculdade de Ciências Médicas, Universidade Estadual de Campinas,
10 Brazil.

11 3. National Institute of Allergy and Infectious Diseases, USA.

12 4. Instituto Gonçalo Moniz, Fiocruz Bahia, Brazil.

13 5. Department of Clinical and Toxicological Analyses, School of
14 Pharmaceutical Sciences, University of Sao Paulo, SP (05508-000), Brazil.

15 6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.

16 7. Instituto Leônidas & Maria Deane, Fiocruz Amazônia, Brazil.

17 8. Centro de Hematologia e Hemoterapia – Hemocentro, Universidade
18 Estadual de Campinas, Brazil.

19 *Correspondence: fabiotmc72@gmail.com.

20 Abstract: 217 words

21 Text: 2,130 words

22 ABSTRACT

23 **Introduction.** Platelets drive endothelial cell activation in many diseases.
24 However, if this occurs in *Plasmodium vivax* malaria is unclear. As platelets have
25 been reported to be activated and to play a role in inflammatory response during
26 malaria, we hypothesized that this would correlate with endothelial alterations
27 during acute illness.

28 **Methods.** We performed platelet flow cytometry of PAC-1 and P-selectin. We
29 measured Platelet markers (CXCL4, CD40L, P-selectin, Thrombopoietin, IL-11) and
30 endothelial markers (ICAM-1, von Willebrand Factor and E-selectin) in plasma with a
31 multiplex-based assay. The values of each mediator were used to generate heatmaps, K-
32 means clustering and Principal Component analysis. In addition, we determined pair-wise
33 Pearson's correlation coefficients to generate correlation networks.

34 **Results.** Platelet counts were reduced, and mean platelet volume increased in
35 malaria patients. The activation of circulating platelets in flow cytometry did not differ
36 between patients and controls. CD40L levels (Median [IQ]: 517 [406-651] vs. 1029 [732-
37 1267] pg/mL, $P=0.0001$) were significantly higher in patients, while P-selectin (Median
38 [IQ]: 17.0 [15.4-20.6] vs. 22.2 [17.6-25.7] ng/mL, $P=0.0621$) and CXCL4 showed a
39 nonsignificant trend towards higher levels in patients. The network correlation
40 approach demonstrated the correlation between markers of platelet and endothelial
41 activation, and the heatmaps revealed a distinct pattern of activation in two subsets
42 of *P. vivax* patients when compared to controls.

43 **Conclusion.** platelet activation occurs in uncomplicated vivax malaria and
44 this correlates with higher endothelial cell activation, especially in a subset of
45 patients.

46 **Keywords:** thrombocytopenia; thrombopoiesis; platelet activation; CD40L; P-
47 selectin; endothelial cell activation.

48 **AUTHOR SUMMARY**

49 Endothelial cell activation is a key process in the pathogenesis of
50 *Plasmodium vivax* malaria. Platelets are classically involved endothelial cell
51 activation in several diseases, but their role in context of vivax malaria remains
52 unclear. Thrombocytopenia is the most common hematological disturbance in *P.*
53 *vivax*-infected patients, and platelets have been implicated in parasitemia control.
54 In this study, we studied the activation of platelets in association with endothelial
55 cell activation in vivax malaria. Platelets retrieved from infected peripheral blood
56 were non-activated when analyzed by flow cytometry; however, they displayed
57 higher mean volume and significantly reduced counts. We also found higher levels
58 of circulating factors associated with platelet activation (especially CD40L),
59 thrombopoiesis and endothelial cell activation in infected patients. Further,
60 through pair-wise correlation and clustering analysis, we found a subgroup of
61 patients showing significant associations between markers of platelet and
62 endothelial activation in a pattern different from that of endemic controls.
63 Collectively, our findings point to a peculiar role of platelets in endothelial cell
64 activation in vivax malaria and indicate a heterogeneous host response in the
65 setting of uncomplicated disease, a finding to be further explored in future studies.

66 INTRODUCTION

67 Thrombocytopenia is the most common hematological alteration in malaria,
68 although there is no definitive mechanistic explanation to its occurrence (1, 2). In
69 a retrospective cohort, patients who died from malaria had lower platelet counts in
70 comparison to those with less severe disease (3). Moreover, *P. vivax* malaria
71 patients with thrombocytopenia showed higher levels of markers of endothelial
72 cell (EC) activation compared to those with normal platelet counts (4) and some
73 grade of platelet activation has been reported during the disease (5). Together,
74 these reports point out to a significant role of platelets in the pathophysiology of
75 malaria.

76 In cerebral malaria, the most severe presentation of the disease, platelets
77 have been shown to accumulate in the brain microvessels of affected children (6).
78 In mice, the adhesion of platelets to brain endothelial cells was crucial for the
79 development of the syndrome (7). In addition, platelets lead to a deleterious
80 inflammatory response in the disease through platelet-factor 4 (PF4), with PF4-
81 KO mice surviving the infection (8). However, PF4 also plays a protective role in
82 the disease, as it mediates *P. falciparum* killing by platelets *in vitro* (9) and *in vivo*,
83 as shown in patients from Southeast Asia, and this was correlated with reduced
84 parasitemias (10).

85 EC activation is present in all malaria species, occurring in both mild and
86 severe cases (11). In terms of pathogenesis, EC activation is important for *P.*
87 *falciparum*-infected erythrocytes adhesion to microvasculature, avoiding
88 immunological clearance and leading to severe disease, while inducing more EC

89 damage (12). *P. vivax*-infected erythrocytes also adhere to EC (13), but the
90 magnitude of the phenomenon is smaller and if this has a role in endothelium
91 pathology and disease severity is not clear (14).

92 While the role of platelets in *P. falciparum* malaria has been extensively
93 studied, its role in the pathogenesis of EC dysfunction during *P. vivax* malaria
94 remains to be investigated. In this study, we show that platelet counts were reduced
95 in *P. vivax* malaria patients, while circulating markers of platelet activation were
96 higher. Importantly, platelet activation markers correlated with those related to
97 endothelial activation, indicating a role for platelets in EC pathology in this
98 disease.

99

100 **METHODS**

101 *Ethics Statement*

102 All subjects enrolled in the study were adults, and samples were taken only
103 after signing of informed consent. The study was approved by the local Research
104 Ethics Committee at Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
105 (FMT-HVD, Manaus, Brazil), under #CAAE: 54234216.1.0000.0005. Sixty-five
106 patients with *P. vivax* malaria, as diagnosed by light microscopy, seen at FMT-
107 HVD and 37 healthy controls were enrolled. Exclusion criteria: under 18 years of
108 age; pregnancy; in use of antimalarials; chronic disease; medication known to
109 interfere with platelet count/function; smoking. After signing the informed

110 consent, 20 mL of venous blood were drawn by venipuncture in a syringe with
111 15% acid citrate dextrose as anticoagulant to minimize in vitro platelet activation.

112

113 *Platelet isolation and poor platelet plasma preparation*

114 Whole blood was centrifuged at 180 g for 18 minutes at room temperature,
115 without brake for gradient formation, to obtain the platelet rich plasma (PRP). The
116 PRP was centrifuged at 100 g for 10 minutes for removal of residual leukocytes,
117 and subsequently centrifuged at 800g for 20 minutes to obtain the platelet pellet,
118 prostaglandin E1 300 nM was used to minimize platelet aggregation. The
119 supernatant of this centrifugation was centrifuged at 1000 g for 10 minutes to
120 obtain platelet poor plasma (PPP).

121

122 *Platelet parameters*

123 Within 15 minutes of sampling, complete blood counts were performed.
124 Platelet activation was assessed in PRP using anti-CD61 antibody, and PAC-1
125 (FITC) and anti-P-selectin (PE) antibodies, by flow cytometry (FACSCanto, BD)
126 and analysis with FlowJo software (Free Star). The same panel was used to assess
127 whether the incubation of PPP (50% v/v for 10 min at 37 °C) from malaria patients
128 was capable to activate platelets from a healthy donor.

129 We also measured circulating factors associated with platelet activation
130 and production in the patients' plasma, using a multiplex-based cytokine assay
131 (R&D Systems): CD40L, P-selectin, PF4 and thrombopoietin (TPO), IL-11, as

132 well as circulating markers of EC activation (ICAM-1, E-selectin, von Willebrand
133 Factor (vWF)). We selected 31 patients for the multiplex assay from a wide range
134 of parasitemias (260 to 25,150 *Pv*-IE/ μ L), so that a wide spectrum of disease
135 burden could be evaluated. This subgroup did not differ from the overall
136 population of patients regarding severity of disease, sex proportion, platelet counts
137 and mean parasitemia. We selected nine controls matched for age and sex. For the
138 network analysis, we used some interpolated results from below standard range.

139

140 *Network and clustering analysis*

141 The values of each circulating factor measured in the plasma samples,
142 hematological parameters and parasitemia from endemic controls and *P. vivax*
143 malaria patients were input in the R software (v 3.4.3) to generate heatmaps and to
144 perform K-means clustering. After running the algorithms, individuals were
145 clustered according to the levels of expression of the mediators in 3 groups, which
146 were named Control, Vivax^{low} and Vivax^{high}. In addition, the same software was
147 used to determine pair-wise Pearson's correlation coefficients to generate
148 correlation networks and the p value to test for non-correlation was evaluated using
149 $p \leq 0.05$ as a cut-off. In order to analyze the structure of the networks, the graphics
150 for the network analysis were customized in the Cytoscape software (v 3.5.1) using
151 the prefuse force-directed layout, which in the equilibrium state for the system of
152 forces, determined by the correlation strength, the edges tend to have uniform
153 length, and nodes that are not connected by an edge tend to be drawn further apart.

154

155 *Statistical Analysis*

156 Fisher's exact test was used for categorical data. Student's t-test was used
157 to compare means between groups with normally distributed data, and data sets
158 with non-normal distributions were compared using the Mann–Whitney test, with
159 $p < 0.05$ considered significant. Data are presented as means and SD unless
160 otherwise stated. Analysis were performed, and the graphs generated in GraphPad
161 Prism5 and R software.

162

163 **RESULTS**

164 *Platelet parameters in malaria patients*

165 Platelet counts were significantly reduced in patients (Mean \pm SD:
166 $91.5 \pm 41.3 \times 10^9/L$ vs. $244.1 \pm 52.1 \times 10^9/L$, $P < 0.0001$), yielding an 88,8% frequency
167 of thrombocytopenia (Figure 1A). Mean Platelet Volume (MPV) was increased in
168 patients (9.2 ± 1.1 fL) compared to controls (8.7 ± 0.6 fL, $P < 0.0126$) (Figure 1B),
169 and was inversely correlated with platelet counts in both patients and control
170 groups (Patients $r = -0.4959$, Controls $r = -0.6898$, both $P < 0.0001$) (Figure 1C).
171 Platelet counts were not correlated with parasitemia.

172

173 *Platelet Activation in vivax malaria*

174 Platelet activation is a feature of some thrombocytopenic infections as well
175 of diseases associated to endothelial cell dysfunction (15, 16). There was no

176 significant difference in the percentage of expression of P-selectin and PAC-1
177 platelets between patients and controls in flow cytometry (Figure 2A-B).

178 In contrast, patients had higher levels of CD40L in plasma (Median [IQ]: 517
179 [406-651] vs. 1029 [732-1267] pg/mL, $P=0.0001$), with a 2-fold increase in
180 comparison to controls. P-selectin showed a trend towards elevated levels in
181 patients (Median [IQ]: 17.0 [15.4-20.6] vs. 22.2 [17.6-25.7] ng/mL, $P=0.0621$), while
182 PF4 levels (Median [IQ]: 784 [584-1239] vs. 1420 [683-2813] ng/mL, $P=0.1236$)
183 were not different between the groups (Figure 2C-E, Table 1). Patients' PPP failed
184 to activate platelets in comparison to PPP from controls (Figure 2F).

185

186 *Thrombopoiesis*

187 Acute reductions in platelet numbers and inflammatory states disturb
188 thrombopoiesis (17, 18). Therefore, we measured the circulating levels of the
189 cytokines thrombopoietin (TPO) and IL-11, important players in the production of
190 platelets in health and disease. An 50% increase in these two markers was observed
191 in malaria patients (Table 1), and they were significantly correlated (Pearson $r =$
192 0.8476 , 95%CI: $0.7049-0.9243$, $P<0.0001$). There was no correlation between
193 TPO and platelet counts (Figure 3).

194

195 *Correlations and networks*

196 Markers of platelet activation, thrombopoiesis and EC activation were
197 significantly higher in *P. vivax* malaria patients in relation to endemic controls.

198 Importantly, all the associations between platelet and EC markers were positive, a
199 change of pattern in relation to controls, in which both negative and positive
200 associations occurred (Figure 4A-B). Parasitemia was significantly correlated
201 with the markers of thrombopoiesis TPO and IL-11 and with ICAM-1 (Figure 4B).

202 Additionally, the heatmap generated from the expression of the analytes
203 revealed a defined separation of controls and two different groups of *P. vivax*
204 malaria patients (Figure 4C). In comparison to endemic control individuals one
205 group of *P. vivax* malaria patients had a lower overall variation in the response.
206 The second group of patients clearly showed a more potent response to the
207 infection, with a higher variation in the expression of platelet activation and EC
208 activation markers. Figure 4D-E displays the value of each pair of correlations.

209

210 **DISCUSSION**

211 In the current study, we aimed to assess platelet activation and its
212 relationship with endothelial cell activation in the context of *P. vivax* malaria.
213 Thrombocytopenia was the most frequent hematological alteration in our cohort
214 and, as previously reported for malaria (1), was correlated to an increase in MPV.
215 Several disease states in which platelets are consumed mainly in the periphery
216 present with the same correlation. The slightly increased MPV in malaria patients
217 could be important during the disease as larger platelets are thought to be more
218 active in comparison to smaller ones, and have been implicated in diseases were

219 endothelial activation and dysfunction play a central role (16). However, in this
220 study, MPV showed only a non-significant correlation with ICAM-1 levels.

221 Adding to the investigation of platelet disturbances during the disease,
222 we also measured the levels of TPO and IL-11, two cytokines central to platelet
223 production. Previous reports have demonstrated a high platelet turnover during
224 malaria (19) and increased in megakaryocyte numbers in bone marrow (20). The
225 observed rise in TPO and IL-11 levels in our cohort indicates that increased platelet
226 production occurs during vivax malaria in response to the reduction in circulating
227 platelet counts. Nonetheless, TPO levels in *P. vivax* patients presented no
228 correlation with platelet counts, as opposed to what would be expected based on
229 the classical "sponge" model – whereby TPO levels are regulated simply by
230 platelet number – of the regulation of thrombopoiesis. These results indicate that
231 during *P. vivax* malaria, thrombopoiesis might be regulated by additional
232 mechanisms known to stimulate TPO production, such as IL-6 or activation of the
233 Ashwell-Morell receptor (21). Interestingly, TPO and IL-11 were positively
234 associated with the markers of platelet and EC activation, highlighting the
235 correlation of thrombopoiesis alterations and inflammatory states (16). Whether
236 these alterations in platelet production in an acute disease as malaria have major
237 implications for platelet function – as has been shown for chronic inflammatory
238 diseases (15) – is a relevant question for future studies.

239 Whether a systemic activation of circulating platelets occur in malaria is
240 still unclear. While a study has reported altered platelet responses after exposure
241 to *P. falciparum* infected erythrocytes (P-IE) *in vitro* (22), direct assessment of

242 platelet activation through flow cytometry has rendered negative results (10, 23).
243 However, evidence of some grade of platelet activation *in vivo*, through
244 measurement of circulating factors, have been shown by other groups (5, 24).
245 Therefore, on the one hand, our flow cytometry results, both in platelets from
246 patients and in platelet stimulation with patients' plasma, are in line with has been
247 previously reported in the literature. On the other hand, our results of a trend
248 towards elevated (albeit not significantly) P-selectin and, especially, elevated
249 CD40L, argue for some grade of systemic platelet activation, leading to platelet
250 degranulation. Interestingly, platelets have been shown to release bioactive
251 sCD40L during vaso-occlusive in sickle cell disease, a finding that implicates
252 platelet-derived sCD40L in vascular events (25). Moreover, incubation of
253 activated platelets with cultured endothelium leads to its activation through
254 CD40L-CD40 interaction (26). However, as CD40L is also a molecule involved
255 in T-cell activation, we cannot exclude that the latter is a relevant source of the
256 sCD40L found in the patients.

257 Endothelial cell activation is a major component of malaria pathogenesis
258 (11), a phenomenon with an extensive participation of platelets in different disease
259 settings (16). As platelets are classically associated with endothelial pathology, we
260 searched for patterns of association between platelet factors and markers of
261 endothelial cell activation. Interestingly, our networks revealed the association of
262 soluble CD40L and P-selectin with ICAM-1 and E-selectin, indicating the
263 interplay between these two cell populations in the disease, with a possible role for
264 platelets in the pathogenesis of endothelial cell activation in vivax malaria. CD40L

265 has been described as a central molecule in the pathogenesis of atherosclerosis and
266 is elevated during vaso-occlusive crisis in sickle cell disease (25), features that
267 argue for a potential causative role of this molecule in EC activation in malaria.

268 Notably, the heatmaps further confirmed a distinct pattern of platelet and
269 endothelial cell activation in a subset of patients (Figure 2), which were more
270 markedly distinct from controls. This finding reinforces the hypothesis that platelet
271 activation and release of granule content plays a role in the endothelium alterations
272 in *P. vivax* malaria (5).

273 A limited small number of patients were included in the multiplex-based
274 assay, limiting the generalizability of the findings and the statistical analyses.
275 Moreover, while the role for platelets in endothelial activation in malaria is
276 indicated by our results and has biological foundation, the mechanisms behind this
277 association were not elucidated. Finally, although all patients included in the study
278 presented with uncomplicated malaria, we did not follow patients throughout their
279 illness to assess potential clinical implications of our findings.

280 In this study, we found evidence of platelet activation during vivax
281 malaria. Importantly, we show that soluble CD40L is elevated during the infection
282 and the positive associations with markers of EC activation indicate that this
283 molecule is a player in the pathogenesis of this disease. Therefore, we believe that
284 future studies to identify the mechanisms of how platelets induce EC pathology in
285 relevant models of vivax malaria are warranted.

286

287 **Conflict of Interest**

288 The authors declare no conflicting interests regarding the findings of the
289 manuscript.

290 **Funding**

291 This work was supported by FAPESP grants #2012/16525-2 and #2017/18611-7.
292 JCKS receives a scholarship from CAPES. JLSF receives a scholarship from
293 FAPESP #2916/12855-9. HN, MVGL, EVP and FTMC are CNPq research
294 fellows.

295 **Acknowledgements**

296 We would like to thank the support of the malaria diagnosis team at Fundação de
297 Medicina Tropical. Cytometric analysis was done at the Flow Cytometry Platform
298 at Instituto Leônidas & Maria Deane, Fiocruz Amazônia. The multiplex was
299 performed at the Laboratório Central de Tecnologias de Alto Desempenho
300 (LaCTAD, University of Campinas).

301 **Meetings**

302 Some of the results from this paper have been previously presented at the Brazilian
303 Congress of the Hematology and Hemotherapy (2018) and the International
304 Conference of Plasmodium vivax Research (2019) in the form of posters.

305 **Corresponding Author**

306 Fabio Trindade Maranhão Costa, PhD, Full Professor, University of Campinas, E-
307 mail: fabiomc72@gmail.com.


308 **References**

- 309 1. Coelho HC, Lopes SC, Pimentel JP, Nogueira PA, Costa FT, Siqueira AM, et al.
310 Thrombocytopenia in Plasmodium vivax malaria is related to platelets phagocytosis. PLoS One.
311 2013;8(5):e63410.
- 312 2. Lacerda MV, Mourão MP, Coelho HC, Santos JB. Thrombocytopenia in malaria: who
313 cares? Mem Inst Oswaldo Cruz. 2011;106 Suppl 1:52-63.
- 314 3. Hanson J, Phu NH, Hasan MU, Charunwatthana P, Plewes K, Maude RJ, et al. The
315 clinical implications of thrombocytopenia in adults with severe falciparum malaria: a
316 retrospective analysis. BMC Med. 2015;13:97.
- 317 4. Gomes LT, Alves-Junior ER, Rodrigues-Jesus C, Nery AF, Gasquez-Martin TO, Fontes CJ.
318 Angiopoietin-2 and angiopoietin-2/angiopoietin-1 ratio as indicators of potential severity of
319 Plasmodium vivax malaria in patients with thrombocytopenia. PLoS One. 2014;9(10):e109246.
- 320 5. Brouwers J, Noviyanti R, Fijnheer R, de Groot PG, Trianty L, Mudaliana S, et al. Platelet
321 activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as
322 biomarkers. PLoS One. 2014;8(6):e64850.
- 323 6. Grau GE, Mackenzie CD, Carr RA, Redard M, Pizzolato G, Allasia C, et al. Platelet
324 accumulation in brain microvessels in fatal pediatric cerebral malaria. J Infect Dis.
325 2003;187(3):461-6.
- 326 7. Sun G, Chang WL, Li J, Berney SM, Kimpel D, van der Heyde HC. Inhibition of platelet
327 adherence to brain microvasculature protects against severe Plasmodium berghei malaria.
328 Infect Immun. 2003;71(11):6553-61.
- 329 8. Srivastava K, Cockburn IA, Swaim A, Thompson LE, Tripathi A, Fletcher CA, et al.
330 Platelet factor 4 mediates inflammation in experimental cerebral malaria. Cell Host Microbe.
331 2008;4(2):179-87.
- 332 9. McMorran BJ, Wieczorski L, Drysdale KE, Chan JA, Huang HM, Smith C, et al. Platelet
333 factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. Science.
334 2012;338(6112):1348-51.
- 335 10. Kho S, Barber BE, Johar E, Andries B, Poespoprodjo JR, Kenangalem E, et al. Platelets
336 kill circulating parasites of all major Plasmodium species in human malaria. Blood. 2018.
- 337 11. Turner GD, Ly VC, Nguyen TH, Tran TH, Nguyen HP, Bethell D, et al. Systemic
338 endothelial activation occurs in both mild and severe malaria. Correlating dermal
339 microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease
340 severity. Am J Pathol. 1998;152(6):1477-87.
- 341 12. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is
342 associated with parasite binding to endothelial protein C receptor. Nature.
343 2013;498(7455):502-5.
- 344 13. Carvalho BO, Lopes SC, Nogueira PA, Orlandi PP, Bargieri DY, Blanco YC, et al. On the
345 cytoadhesion of Plasmodium vivax-infected erythrocytes. J Infect Dis. 2010;202(4):638-47.
- 346 14. Barber BE, William T, Grigg MJ, Parameswaran U, Piera KA, Price RN, et al. Parasite
347 biomass-related inflammation, endothelial activation, microvascular dysfunction and disease
348 severity in vivax malaria. PLoS Pathog. 2015;11(1):e1004558.
- 349 15. Nhek S, Clancy R, Lee KA, Allen NM, Barrett TJ, Marcantoni E, et al. Activated Platelets
350 Induce Endothelial Cell Activation via an Interleukin-1 β Pathway in Systemic Lupus
351 Erythematosus. Arterioscler Thromb Vasc Biol. 2017;37(4):707-16.
- 352 16. Martin JF, Kristensen SD, Mathur A, Grove EL, Choudry FA. The causal role of
353 megakaryocyte–platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol.
354 2012;9(11):658-70.
- 355 17. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, et al. Interleukin-6
356 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis.
357 Blood. 2001;98(9):2720-5.

- 358 18. Nishimura S, Nagasaki M, Kunishima S, Sawaguchi A, Sakata A, Sakaguchi H, et al. IL-1 α
359 induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. *J*
360 *Cell Biol.* 2015;209(3):453-66.
- 361 19. Karanikas G, Zedwitz-Liebenstein K, Eidherr H, Schuetz M, Sauerma R, Dudczak R, et
362 al. Platelet kinetics and scintigraphic imaging in thrombocytopenic malaria patients. *Thromb*
363 *Haemost.* 2004;91(3):553-7.
- 364 20. Abdalla SH. Hematopoiesis in human malaria. *Blood Cells.* 1990;16(2-3):401-16;
365 discussion 17-9.
- 366 21. Eto K, Kunishima S. Linkage between the mechanisms of thrombocytopenia and
367 thrombopoiesis. *Blood.* 2016;127(10):1234-41.
- 368 22. Inyang AL, Sodeinde O, Okpako DT, Essien EM. Platelet reactions after interaction with
369 cultured *Plasmodium falciparum* infected erythrocytes. *Br J Haematol.* 1987;66(3):375-8.
- 370 23. de Mast Q, de Groot PG, van Heerde WL, Roestenberg M, van Velzen JF, Verbruggen B,
371 et al. Thrombocytopenia in early malaria is associated with GP1b shedding in absence of
372 systemic platelet activation and consumptive coagulopathy. *Br J Haematol.* 2010;151(5):495-
373 503.
- 374 24. Facer CA, Theodoridou A. Elevated plasma levels of P-selectin (GMP-140/CD62P) in
375 patients with *Plasmodium falciparum* malaria. *Microbiol Immunol.* 1994;38(9):727-31.
- 376 25. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is
377 elevated in sickle cell anemia: potential role for platelet-mediated inflammation. *Arterioscler*
378 *Thromb Vasc Biol.* 2006;26(7):1626-31.
- 379 26. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, et al.
380 CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells.
381 *Nature.* 1998;391(6667):591-4.


382


383 **Figures and Tables**



386 **Figure 1. Platelet counts and volume. A)** Platelet counts were significantly
387 reduced in malaria patients. **B)** MPV was moderately increased in patients. **C)**
388 Platelet count and MPV were inversely correlated in both patients and controls.

389







392

393 **Figure 2. Platelet activation.** Percentage of platelet activation by **A)** anti-P-
394 selectin and **B)** PAC-1 staining (N=11). **C)** Levels of sCD40L. **D)** Levels of
395 sPselectin. **E)** Levels of PF4 (Controls, n=9, Patients n=31). **F)** Plasma from
396 malaria patients failed to induce activation of controls platelets. We used
397 thrombin as a positive control

398







400

401 **Figure 3. Levels of thrombopoietic cytokines in *P. vivax* malaria. A)** Elevated
402 levels of TPO in patients compared to controls. **B)** Elevated IL-11 in patients
403 compared to controls. **C)** Significant association between TPO and IL-11
404 ($r=0.8476$, 95%CI: 0.7049-0.9243, $P<0.0001$), indicating a concerted stimulus to
405 platelet production. **D)** Lack of association between TPO and platelet counts,
406 indicating that the “sponge model” does not solely explain regulatory mechanisms
407 of TPO production in this disease.

408



409



413 **Figure 4. Correlation between markers of platelet and endothelial cell**
 414 **activation.** Networks of the correlations between platelet parameters and markers
 415 of endothelial cell activation in controls **(A)** and patients **(B)**, using a prefuse force-
 416 directed layout done in Cytoscape software (v 3.5.1). **C)** Heatmap obtained from
 417 the normalized expression of parasitemia, platelet parameters and markers of
 418 endothelial cell activation, showing three distinct clusters of controls and two
 419 groups of patients. Yellow: Controls; Orange: low parasitemia; Brown: moderate

420 parasitemia; Gray: high parasitemia. Value for each pair of correlation between the
421 parameters measured in the plasma from controls (**D**) and patients (**E**).

422

423 **Table 1. Plasma levels of markers of platelet activation and production.**

Parameter	Controls (n=9)	Patient (n=31)	P
Median [IQ 25-75]			
CD40L (pg/mL)	517 [406-651]	1029 [732-1267]	0.0001
P-Selectin (ng/mL)	17.0 [15.4-20.6]	22.2 [17.6-25.7]	0.0621
PF4 (pg/mL)	784 [584-1239]	1420 [683-2813]	0.1236
TPO (pg/mL)	2046 [1652-2194]	2996 [2554-3402]	<0.0001
IL-11 (pg/mL)	3547 [2904-4298]	5748 [4687-6448]	<0.0001

424